Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Imaging Canada Liquidating Corp IMRSQ

Healthcare Medical Devices
IMRIS Inc designs, manufactures and markets Image-guided therapy systems that improves the effectiveness of therapy delivery. Its main product is the Visius surgical theater. The company provides its products to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular and cardiovascular markets. The firm is focused on bringing enhanced visualization to the point of therapy delivery and is spread across Canada, United States, Europe and the Middle East and Asia-Pacific.


GREY:IMRSQ - Post by User

Imaging Canada Liquidating Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by erasmus2010on Jun 15, 2010 4:05pm
655 Views
Post# 17191324

Two Analysts’ ratings

Two Analysts’ ratings

Jan 27 2010 Douglas Loe at Versant Partners initiated with a Buy rating and one-year price target of $9.75. Offices in Toronto and Montreal

June 14 2010 - Paradigm Capital initiated coverage with a buy rating and $9 price target Offices in Toronto and Calgary
Both Canadian research firms new to me, anyone have an opinion on their track records or reputation. Also I would like to know who else has recent reports on Imris?

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities